The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 15, 2019 at 10:22 PM.

  1. #1 cafead, Sep 15, 2019 at 10:22 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Biotech stocks rebounded in last week after declining modestly in the previous week.

    Some of the drugs that cleared the FDA hurdle this week include Ardelyx Inc (NASDAQ: ARDX)'s constipation drug Ibsrela; South African drugmaker Apsen Pharmacare's hydroxyprogesterone caproate, indicated to prevent preterm birth in pregnant women; and GlaxoSmithKline plc (NYSE: GSK)'s Nucala for treating severe eosinophilic asthma in children, ages 8-11 years.

    The week turned out to be a disappointing one for a few nano- and micro-cap stocks, which reported negative clinical trial readouts. Tocagen Inc (NASDAQ: TOCA) tumbled about 78% after its brain cancer drug failed to ace a late-stage study and Ritter Pharmaceuticals Inc (NASDAQ: RTTR)'s pipeline asset to treat lactose intolerance also stumbled in a late-stage study, sending its shares to a record low.

    Here are the key catalysts a biotech investor needs to focus on for the upcoming week.

    article source
     
    Quote

Reply to Thread